The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial

Journal of Urology

Volumn 190, Issue 3, 2013, Pages 857-862

  Gontero, Paolo ^a   Oderda, Marco ^a   Mehnert, Anja ^e   Gurioli, Alberto ^a   Marson, Francesco ^a   Lucca, Ilaria ^a   Rink, Michael ^e   Schmid, Marianne ^e   Kluth, Luis A ^e   Pappagallo, Giovanni ^b   Sogni, Filippo ^c   Sanguedolce, Francesco ^d   Schiavina, Riccardo ^d   Martorana, Giuseppe ^d   Shariat, Shahrokh F ^f   Chun, Felix ^e  

^a UNIVERSITY OF TURIN   (Italy)

^b Noale Hospital   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BCG Connaught; gemcitabine; quality of life; risk assessment; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; GEMCITABINE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INSTILLATION; DRUG TOLERABILITY; DYSURIA; EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30 VERSION 3.0; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS OF VARIANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE SUPERFICIAL BLADDER CANCER SPECIFIC 24 QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

BACILLUS CALMETTE-GUÉRIN; BCG; BCG CONNAUGHT; CARCINOMA IN SITU; CIS; COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; CTCAE; GEM; GEMCITABINE; NMIBC; NONMUSCLE INVASIVE BLADDER CANCER; QOL; QUALITY OF LIFE; RISK ASSESSMENT; TRANSURETHRAL RESECTION; TUR; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84881481043     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.03.097     Document Type: Article

References (17)

1. M. Babjuk, W. Oosterlinck, R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997
2. P. Gontero, A. Bohle, P.U. Malmstrom The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer Eur Urol 57 2010 410
3. M.D. Shelley, T.J. Wilt, J. Court Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 93 2004 485
4. P. Gontero, G. Casetta, G. Maso Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC) Eur Urol 46 2004 339
5. G. Dalbagni, P. Russo, B. Bochner Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder J Clin Oncol 24 2006 2729
6. R. Addeo, M. Caraglia, S. Bellini Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance J Clin Oncol 28 2009 543
7. M.D. Shelley, G. Jones, A. Cleves Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review BJU Int 109 2012 496
8. K. Hendricksen, J.A. Witjes Treatment of intermediate-risk non-muscle-invasive bladder cancer (NMIBC) Eur Urol Suppl 6 2007 800
9. A. Trotti, A.D. Colevas, A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176
10. N.K. Aaronson, S. Ahmedzai, B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365
11. EORTC Quality of Life: Bladder Cancer: EORTC QLQ-BLS24, EORTC QLQ-BLM30 http://groups.eortc.be/qol/bladder-cancer-eortc-qlq-bls24-eortc-qlq-blm30 Accessed June 11, 2013
12. K.F. Schulz, D.G. Altman, D. Moher CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials Ann Int Med 152 2010 726
13. S. Hinotsu, H. Akaza, S. Isaka Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study Urology 67 2006 545
14. J.A. Martínez-Piñeiro, L. Martínez-Piñeiro, E. Solsona Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against the recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial J Urol 174 2005 1242
15. L. Bendary, S. Khalil, A. Shahin Intravesical gemcitabine versus bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: short term comparative study J Urol 185 suppl. 2011 e664 abstract 1655
16. M. Porena, M. Del Zingaro, M. Lazzeri Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study Urol Int 84 2010 23
17. G. Di Lorenzo, S. Perdonà, R. Damiano Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial Cancer 116 2010 1893